# OnCo record blood-count-and-kidney-monitoring-during-radioligand-therapy (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "blood-count-and-kidney-monitoring-during-radioligand-therapy" ;
  schema:name "Blood count, kidney and liver monitoring during lutetium-177 radioligand therapy"@en ;
  schema:alternateName "blood tests before Lutathera"@en, "blood tests before Pluvicto"@en, "low blood counts on Lutathera"@en, "low blood counts on Pluvicto"@en, "myelosuppression on radioligand therapy"@en, "lymphopenia on lutetium-177"@en, "kidney protection with amino acids during PRRT"@en, "lysine and arginine infusion"@en, "Lutathera dose reduction"@en, "Pluvicto dose reduction"@en, "renal toxicity of lutetium-177"@en, "hyperkalaemia with the amino acid infusion"@en ;
  schema:description "Lutetium-177 treatments (Lutathera, Pluvicto) can lower blood counts and affect the kidneys and liver. Blood is tested before every dose, and a dose may be delayed, reduced or stopped if results fall too far. With Lutathera, an amino acid drip protects the kidneys. Tell your team right away about bleeding, bruising, fever or passing much less urine. Your own team's plan comes first."@en ;
  schema:url <https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/lutetium-177-therapy-home-radiation-safety/>, <https://onco.cc/protocols/radionuclide-therapy-patient-release-criteria/>, <https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/>, <https://onco.cc/protocols/dry-mouth-from-cancer-drugs-and-radionuclide-therapy/>, <https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/>, <https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/>, <https://onco.cc/protocols/renal-dose-adjustment-of-anticancer-drugs/>, <https://onco.cc/protocols/febrile-neutropenia-first-hour/>, <https://onco.cc/technologies/lu177-radioligand-therapy/> ;
  onco:drugs <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/pluvicto/> ;
  onco:terms <https://onco.cc/terms/prrt-term/>, <https://onco.cc/terms/thrombocytopenia/>, <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/neutropenia/> .
